Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

Sergey G. Klochkov, Margarita E. Neganova, Nagendra Sastry Yarla, Madhukiran Parvathaneni, Bechan Sharma, Vadim V. Tarasov, George Barreto, Sergey O. Bachurin, Ghulam Md Ashraf, Gjumrakch Aliev*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Citations (Scopus)

Abstract

Ras proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.

Original languageEnglish
Pages (from-to)128-134
Number of pages7
JournalSeminars in Cancer Biology
Volume56
DOIs
Publication statusPublished - Jun 2019
Externally publishedYes

Keywords

  • Cancer
  • Farnesyltransferase
  • Farnesyltransferase inhibitor
  • Ras protein
  • Therapy

Fingerprint

Dive into the research topics of 'Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy'. Together they form a unique fingerprint.

Cite this